Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs

Drug Metabolism and Disposition

Volumn 25, Issue 2, 1997, Pages 270-273

  Okuda, Haruhiro ^b   Nishiyama, Takahito ^b   Ogura, Yasuro ^b   Nagayama, Sekio ^b   Ikeda, Kenichiro ^b   Yamaguchi, Shuji ^b   Nakamura, Yoshimasa ^b   Kawaguchi, Kazumasa ^b   Watabe, Tadashi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL)URACIL; ANTINEOPLASTIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SORIVUDINE; TEGAFUR; UNCLASSIFIED DRUG; URACIL DERIVATIVE; 5 BROMOURACIL; 5-(2-BROMOVINYL)URACIL; ANTINEOPLASTIC ANTIMETABOLITE; ANTIVIRUS AGENT; DRUG DERIVATIVE; OXIDOREDUCTASE; URACIL ARABINOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; ATROPHY; BONE MARROW DISEASE; COLONY FORMING UNIT GM; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG TISSUE LEVEL; FEMALE; INTESTINE MUCOSA; LETHALITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TOXICOKINETICS; ANIMAL; AREA UNDER THE CURVE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; LIVER; METABOLISM; PATHOLOGY; SMALL INTESTINE; TISSUE DISTRIBUTION; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; AREA UNDER CURVE; BONE MARROW DISEASES; BROMOURACIL; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG SYNERGISM; FEMALE; INTESTINE, SMALL; LIVER; OXIDOREDUCTASES; RATS; RATS, WISTAR; TEGAFUR; TISSUE DISTRIBUTION;

EID: 0031024879     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare: A report on investigation of side effects of sorivudine: deaths caused by interactions between sorivudine and 5-FU prodrugs (in Japanese). June, 1994.
2. H. Fujita, M. Sugiyama, and K. Kimura: Pharmacokinetics of Futraful (FT 207) for clinical application. In "Chemotherapy (Proceedings of the Ninth International Congress of Chemotherapy, London, 1975)" (K. Hellmann and T. A. Connors, eds.), Vol. 8. pp. 51-57. Plenum Press, New York, 1976.
3. T. Nishimoto, N. Yokoyama, H. Sakamoto, K. Ohata, S. Kohno, K. Murai, and H. Tatsumi: Studies on the metabolic fate of Brovavir (YN-72) II; metabolism in rats. Iyakuhin Kenkyu 21, 378-389 (1990); Chem. Abstr. 114, 17025 (1991).
4. T. Nishimoto, N. Yokoyama, H. Sakamoto, K. Ohata, S. Kohno, K. Murai, and H. Tatsumi: Studies on the metabolic fate of Brovavir (YN-72) II; metabolism in rats. Iyakuhin Kenkyu 21, 378-389 (1990); Chem. Abstr. 114, 17025 (1991).
5. C. Desgranges, G. Razaka, E. D. Clercq, P. Herdewijn, J. Balzarini, F. Drouillet, and H. Bricaud: Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res. 46, 1094-1101 (1986).
6. Z.-H. Lu, R. Zhang, and R. B. Diasio: Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver; biochemical and immunological properties. Biochem. Pharmacol. 46, 945-952 (1993).
7. R. B. Diasio and B. E. Harris: Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16, 215-237 (1989).
8. S. Sakata, S. Shibuya, H. Machida, H. Yoshino, K. Hirota, S. Senda, K. Ikeda, and Y. Mizuno: Synthesis and antiherpesviral activity of 5-C-substituted uracil nucleosides. Nucleic Acid Res., Symp. Ser. 8, s39-s42 (1980).
9. A. S. Jones, G. Verhelst, and R. T. Walke: The synthesis of the potent anti-herpes virus agent, E-5(2-bromovinyl)-2′-deoxyuridine and related compounds. Tetrahedron Lett. 45, 4415-4418 (1979).
10. T. Marunaka, Y. Umeno, K. Yoshida, M. Nagamachi, Y. Minami, and S. Fujii: High-pressure liquid chromatographic determination of Ftorafur (1-(tetrahydro-2-furanyl)-5-fluorouracil) and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus Ftorafur. J. Pharm. Sci. 69, 1296-1300 (1980).
11. K. Ikenaka, T. Shirasaka, S. Kitano, and S. Fujii: Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 70, 353-359 (1979).
12. D. J. T. Porter, W. G. Chestnut, L. C. E. Taylor, B. M. Merrill, and T. Spector: Inactivation of dihydropyrimidine dehydrogenase by 5-iodouracil. J. Biol. Chem. 266, 19988-19994 (1991).
13. H. Yokota, P. Fernandez-Salguero, H. Furuya, K. Lin, O. W. McBride, B. Podschun, K. D. Schnackerz, and F. J. Gonzalez: cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J. Biol. Chem. 269, 23192-23196 (1994).
14. 2-deficient diet. Seikagaku 68, 938 (1996).